: Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatit...

In an exceptional showcase of innovation and scientific advancement, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology company dedicated to the development of bioengineered human tissues, has announced its parti...

Alzheimer s disease (AD) stands as one of the most pressing public health challenges of our era, with trajectories marked by increasing prevalence rates among aging populations. In response to this crisis, Cognition The...

Regeneron Advances Therapeutic Frontier at ASH: Novel Data in Multiple Myeloma, Lymphoma, and Paroxysmal Nocturnal Hemoglobinuria Unveiled Regeneron Pharmaceuticals recently showcased significant progress in its hematol...

In a pioneering move in the field of ophthalmic gene therapy, Opus Genetics has achieved a significant milestone by dosing the first participant in its OPGx-BEST1 Phase 1/2 clinical trial aimed at treating Best Disease,...

In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The com...

AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biote...

Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Amon...

In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine...

: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agen...

At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the compa...

Expanding the Horizons of Immunotherapy: Advances in Werewolf Therapeutics’ PREDATOR and INDUKINE Platforms The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations designed to enhance t...

: This article delves into the recent developments and promising advancements announced by Elicio Therapeutics, a clinical-stage biotechnology leader in cancer immunotherapy. By examining the emerging data from their on...

Nurix Therapeutics has recently made significant strides in the field of oncology and immunology with their pioneering research and development programs. Building upon a series of compelling studies and validatory precl...

Innovative Therapeutics in Virology: Assembly Biosciences Unveils Promising Data on Capsid Assembly Modulators and Novel InhibitorsIn the realm of antiviral research, Assembly Biosciences has emerged as a significant pl...

Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle ag...